Ind Euro Pharma Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
- Paid Up Capital ₹ 19.94 Cr
- Company Age 32 Year, 8 Days
- Last Filing with ROC 31 Mar 2020
- Revenue Growth %
- Profit Growth -98.55%
- Ebitda -98.55%
- Net Worth -0.70%
- Total Assets -0.02%
About Ind Euro Pharma
Ind Euro Pharma Limited (IEPL) is a Public Limited Indian Non-Government Company incorporated in India on 22 January 1993 and has a history of 32 years. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 19.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sudarshan Narasimhamurthy, Sundar Kanakur, and Chandra Balekay serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85110KA1993PLC013919
- Company No.
013919
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Jan 1993
- Date of AGM
29 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Ind Euro Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudarshan Narasimhamurthy  | Director | 09-Sep-2010 | Current |
| Sundar Kanakur | Whole-Time Director | 22-Jan-1993 | Current |
| Chandra Balekay | Director | 22-Jan-1993 | Current |
Financial Performance of Ind Euro Pharma.
Ind Euro Pharma Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 98.55% decrease in profit. The company's net worth dipped by a decrease of 0.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ind Euro Pharma?
In 2019, Ind Euro Pharma had a promoter holding of 28.54% and a public holding of 71.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhumica-Extracts Private LimitedSudarshan Narasimhamurthy is a mutual person
- Fair Light Finance Limited .
Sudarshan Narasimhamurthy, Sundar Kanakur and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ind Euro Pharma?
Unlock and access historical data on people associated with Ind Euro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ind Euro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ind Euro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
